159
Participants
Start Date
April 14, 2015
Primary Completion Date
May 26, 2016
Study Completion Date
May 26, 2016
TNX-102 SL
1x 2.8mg TNX-102 SL Sublingual tablet
Neurobehavioral Research, Inc., Cedarhurst
Atlanta Center For Medical Research, Atlanta
Sarkis Clinical Trials, Lake City
Clinical Neuroscience Solutions, Inc., Orlando
Compass Research North, LLC, Leesburg
Tuscaloosa VA Medical Center, Tuscaloosa
University Hospitals Case Medical Center, Cleveland
University of Cincinnati College of Medicine, Cincinnati
Great Lakes Clinical Trials, Chicago
Premier Psychiatric Research Institute, Inc., Lincoln
Clinical Trials of Texas, San Antonio
Noesis Pharma, Phoenix
Altea Research, Las Vegas
Cns, Inc., Torrance
Synergy Clinical Research, National City
CESAMH, San Diego
Sun Valley Research Center, Imperial
Excell Research, Inc, Oceanside
CITRIALS, Riverside
Neuropsychiatric Research Center of Orange County, Orange
Northwest Clinical Research Center, Bellevue
Novex Clinical Research, New Bedford
Tonix Pharmaceuticals, Inc.
INDUSTRY